# FORM 4

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20040

OMB APPROVAL

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

#### Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					UI	Section	1 30(1	1) 01 111	e ilivesi	шеш	Company Act	01 1940								
1. Name and Address of Reporting Person*  BOGER JOSHUA S						2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC /									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner					
(Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS						A [ \			nsaction	n (Mor	nth/Day/Year)	Officer (give title below)  Officer (give title below)								
INCORPORATED 50 NORTHERN AVENUE						/22/20		nt. Date	e of Orio	ninal F	iled (Month/D	6. Indiv	idual or .	Joint/Group	) Filing (	Check An	olicable			
(Street)					-	Line)  X Form filed by One Reporting Person  Form filed by More than One Reporting														
	BOSTON MA 02210														Form f Persor		e than (	One Repor	ting	
(City)	(5)		(Zip) ====================================	Non-Deri	vative	Sec	uriti	ies A	cauir	ed C	isnosed (	of or B	enefic	ially	Owner	<u> </u>				
1. Title of Security (Instr. 3)  2. Transact Date (Month/Day			on	2A. Deemed Execution D		l Pate,	3. Transaction Code (Instr. 8)		A. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and		(A) or		5. Amou Securiti Benefic Owned	i. Amount of Securities Beneficially Dwned Following		Direct Cludirect Etr. 4)	7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price		Reporte Transac (Instr. 3	tion(s)		(	Instr. 4)	
Common	Common Stock			10/22/2014					M		4,800	A	<b>\$10</b> .	10.41 3		3,695		D		
Common Stock				10/22/2014					M		1,300	A	\$ <del>17</del> .	7.16 3		4,995	D			
Common Stock		10/22/2014					M		4,400	A	\$35.	35.64 34		),395 D		D				
Common Stock			10/22/2014					S <sup>(1)</sup>		5,400	D	\$106.8	.83 <sup>(2)(3)</sup> 34		3,995	D				
Common Stock		10/22/2014					S <sup>(1)</sup>		1,600	D	\$107.4	49 <sup>(2)(4)</sup> 34		2,395	395 E					
Common Stock		10/22/2014					S <sup>(1)</sup>		2,800	D	\$108.8	33 33 33 33 33 33 33 33 33 33 33 33 33		9,595	05 E					
Common	Stock			10/22/20	014				S <sup>(1)</sup>		700	D	\$109.8	2(2)(6)	338,895		]	D		
Common	Stock														13,286			I 4	401(k)	
Common	Stock														300,000			I S	Common Stock neld in rust <sup>(7)</sup>	
		Т	able								sposed of				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transa Code ( 8)			vative urities uired or oosed o) tr. 3, 4	6. Date Exel Expiration I (Month/Day		ate	7. Title and Amount of Securities Underlying Derivative Secu (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly C	0. Ownership Form: Direct (D) or Indirect I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exerc	isable	Expiration Date	Title	Amou or Numb of Share	er						
Stock Option (right to buy)	\$10.41	10/22/2014			M			4,800	(	8)	02/02/2015	Common Stock	4,80	0	\$0.00	67,388	3	D		
Stock Option (right to buy)	\$17.16	10/22/2014			M			1,300	(	8)	07/19/2015	Common Stock 1,30		0	\$0.00	0 49,900		D		
Stock Option (right to buy)	\$35.64	10/22/2014			M			4,400	(	8)	02/01/2016	Common Stock	4,40	0	\$0.00	591,20	0	D		

### **Explanation of Responses:**

- $1.\ Transaction\ made\ pursuant\ to\ Dr.\ Boger's\ company\ approved\ trading\ plan\ under\ Rule\ 10b5-1.$
- 2. Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 3. Open market sales reported on this line occurred at a weighted average price of \$106.83 (range \$106.21 to \$107.20).
- 4. Open market sales reported on this line occurred at a weighted average price of \$107.49 (range \$107.22 to \$108.16).
- 5. Open market sales reported on this line occurred at a weighted average price of \$108.87 (range \$108.44 to \$109.36).

- 6. Open market sales reported on this line occurred at a weighted average price of \$109.82 (range \$109.57 to \$110.49).
- $7. \ Common \ stock \ held \ in \ grantor \ retained \ annuity \ trusts.$
- 8. Fully vested.

### Remarks:

Kenneth L. Horton, Attorney-10/23/2014 In-Fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.